In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Christophe Bancel, CEO of TISSIUM. He provides information about the incredible material technology his company offers, enabling a replacement for human tissue. Based on the mix of three polymers, the firm can vary the characteristics such that it can be used for muscle or a section of colon or some other soft tissue application. Specifically, the following questions are addressed.

• Your company specializes in tissue reconstruction using something called biomorphic programmable polymers. Can you explain what that is?
• What are the potential applications for this type of technology?
• So is this a raw material, a medical device, or a bit of both?
• Does the material completely breakdown as healing occurs or does some of it remain to aid with strength?
• What has occurred already with regard to market launch/regulatory reviews and what are the next stages for the company?

Listen to this episode and see what you think of these programmable polymers. If you’d like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at [email protected].

Send us a text

For more medtech news and information, visit www.mpomag.com.